argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that members of management will participate in two upcoming investor conferences in June.
argenx to Present at Upcoming June 2023 Investor Conferences Read More »
New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a Phase 2 trial of patients with relapsing multiple sclerosis.
Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, published the Annual Report with full year audited consolidated financial results for the year ended 31 December 2022.
Kinarus Therapeutics Group Reports 2022 Annual Results Read More »
Ascentage Pharma announced that the Center for Drug Evaluation of China National Medical Products Administration has recommended olverembatinib, Ascentage Pharma’s lead novel drug candidate, for a Breakthrough Therapy Designation for the treatment of patients with succinate dehydrogenase -deficient gastrointestinal stromal tumor who had received first-line treatment.
Selvita S.A., one of the largest contract research organization companies in Europe, has published a financial report for Q1 2023*.
IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that all participating study sites in the Phase IIb study of pirepemat are activated and recruiting patients.
Yuhan Corporation announced on the 30th of May that it has signed an in-license agreement with J INTS BIO for a Tyrosine Kinase Inhibitor targeting HER2, ‘JIN-A04’.
Hinge Bio, Inc., a privately-held biotechnology company, announced that Juha Punnonen, M.D., Ph.D. has joined the company as Chief Development Officer.
Juha Punnonen, M.D., Ph.D. Joins Hinge Bio as Chief Development Officer Read More »
ValnevaSE, a specialty vaccine company, announced that its senior management will attend the Jefferies Healthcare Conference, Goldman Sachs Annual Global Healthcare Conference and the Stifel European Healthcare Conference.
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June 2023 Read More »
Akebia announced it will submit a new NDA targeting CKD patients on dialysis, which will not involve additional trials.
FDA Gives Akebia Glimmer of Hope for Rejected CKD-Related Anemia Drug Read More »
